Metabolomic and genomic prediction of common diseases in 700,217 participants in three national biobanks

Identifying individuals at high risk of chronic diseases via easily measured biomarkers could enhance efforts to prevent avoidable illness and death. Using ’omic data can stratify risk for many diseases simultaneously from a single measurement that captures multiple molecular predictors of risk. Her...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature communications 2024-11, Vol.15 (1), p.10092-14, Article 10092
Hauptverfasser: Barrett, Jeffrey C., Esko, Tõnu, Fischer, Krista, Jostins-Dean, Luke, Jousilahti, Pekka, Julkunen, Heli, Jääskeläinen, Tuija, Kangas, Antti, Kerimov, Nurlan, Kerminen, Sini, Kolde, Anastassia, Koskela, Harri, Kronberg, Jaanika, Lundgren, Sara N., Lundqvist, Annamari, Mäkelä, Valtteri, Nybo, Kristian, Perola, Markus, Salomaa, Veikko, Schut, Kirsten, Soikkeli, Maiju, Soininen, Pasi, Tiainen, Mika, Tillmann, Taavi, Würtz, Peter
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Identifying individuals at high risk of chronic diseases via easily measured biomarkers could enhance efforts to prevent avoidable illness and death. Using ’omic data can stratify risk for many diseases simultaneously from a single measurement that captures multiple molecular predictors of risk. Here we present nuclear magnetic resonance metabolomics in blood samples from 700,217 participants in three national biobanks. We built metabolomic scores that identify high-risk groups for diseases that cause the most morbidity in high-income countries and show consistent cross-biobank replication of the relative risk of disease for these groups. We show that these metabolomic scores are more strongly associated with disease onset than polygenic scores for most of these diseases. In a subset of 18,709 individuals with metabolomic biomarkers measured at two time points we show that people whose scores change have different risk of disease, suggesting that repeat measurements capture changes both to health status and disease risk possibly due to treatment, lifestyle changes or other factors. Lastly, we assessed the incremental predictive value of metabolomic scores over existing clinical risk scores for multiple diseases and found modest improvements in discrimination for several diseases whose clinical utility, while promising, remains to be determined. Identifying individuals at high risk for chronic diseases can improve prevention. Here, the authors show that blood metabolomics scores effectively stratify disease risk and compare favorably to genetic and clinical scores in population biobanks.
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-024-54357-0